What is Retatrutide?
Retatrutide (LY3437943) represents the next evolution in incretin-based peptide research. Developed by Eli Lilly, this novel compound is a triple agonist that simultaneously activates three key metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.
While semaglutide and tirzepatide have dominated metabolic research, retatrutide's addition of glucagon receptor agonism opens new avenues for understanding energy expenditure, hepatic metabolism, and body composition changes.
The Triple Agonist Mechanism
Understanding the Three Receptors
GLP-1 Receptor (GLP-1R)
GIP Receptor (GIPR)
Glucagon Receptor (GCGR)
Synergistic Effects
The triple agonist approach creates unique metabolic effects:
| Receptor | Primary Effect | Contribution |
|---|---|---|
| GLP-1R | Appetite suppression | Reduced food intake |
| GIPR | Insulin enhancement | Improved glucose handling |
| GCGR | Energy expenditure | Increased calorie burning |
The glucagon component distinguishes retatrutide by potentially increasing energy expenditure—burning more calories rather than just reducing intake.
Clinical Trial Results
Phase 2 Trial (2023)
The landmark phase 2 trial published in the *New England Journal of Medicine* demonstrated remarkable results:
Study Design:
Key Findings:
| Dose | Mean Weight Loss | ≥5% Weight Loss | ≥15% Weight Loss |
|---|---|---|---|
| 1mg | 8.7% | 82% | 29% |
| 4mg | 17.1% | 93% | 67% |
| 8mg | 22.8% | 100% | 83% |
| 12mg | 24.2% | 100% | 93% |
The 12mg dose achieved 24.2% mean weight loss—the highest ever reported in a phase 2 obesity trial with any pharmacological agent.
Comparison to Other Agents:
| Compound | Mechanism | Max Weight Loss (Trials) |
|---|---|---|
| Semaglutide 2.4mg | GLP-1 | ~15-17% |
| Tirzepatide 15mg | GLP-1/GIP | ~21-22% |
| Retatrutide 12mg | GLP-1/GIP/GCGR | ~24% |
Metabolic Improvements
Beyond weight loss, the trial documented:
Phase 3 Program
Eli Lilly's phase 3 program (TRIUMPH) is examining:
How Retatrutide Works: Detailed Mechanism
Appetite and Food Intake
Like other GLP-1 agonists, retatrutide reduces hunger through:
Energy Expenditure (The Glucagon Effect)
The glucagon receptor component provides unique effects:
Hepatic Effects:
Adipose Tissue Effects:
Net Effect:
The body burns more calories at rest, complementing the reduced intake from GLP-1/GIP effects.
Blood Sugar Balance
Despite glucagon's glucose-raising effects, retatrutide maintains glycemic control:
Peptide Profile
| Property | Details |
|---|---|
| Full Name | Retatrutide (LY3437943) |
| Developer | Eli Lilly |
| Type | Triple agonist peptide |
| Targets | GLP-1R, GIPR, GCGR |
| Administration | Once weekly (subcutaneous) |
| Half-life | ~6 days (estimated) |
| Form | Solution for injection (trials) |
Dosage Protocols in Research
Clinical Trial Titration
The phase 2 trial used gradual dose escalation:
Escalation Schedule (12mg Target):
| Weeks | Dose |
|---|---|
| 1-4 | 0.5mg weekly |
| 5-8 | 1mg weekly |
| 9-12 | 2mg weekly |
| 13-16 | 4mg weekly |
| 17-20 | 8mg weekly |
| 21-48 | 12mg weekly |
This 20-week titration to full dose minimizes gastrointestinal effects while achieving target exposure.
Research Considerations
For researchers working with retatrutide:
Comparing Incretin Agonists
Evolution of Metabolic Peptides
| Generation | Example | Receptors | Weight Loss |
|---|---|---|---|
| 1st Gen | Liraglutide | GLP-1 | ~8% |
| 2nd Gen | Semaglutide | GLP-1 (high potency) | ~15% |
| Dual | Tirzepatide | GLP-1 + GIP | ~21% |
| Triple | Retatrutide | GLP-1 + GIP + GCGR | ~24% |
Enjoying this article?
Subscribe to get notified when we publish new experiment reports and research findings.
No spam, unsubscribe anytime.
Mechanism Comparison
Semaglutide (GLP-1 only):
Tirzepatide (GLP-1 + GIP):
Retatrutide (Triple):
Safety Profile in Research
Phase 2 Observations
Gastrointestinal (most common):
GI effects generally decreased with continued treatment and slower titration.
Other Reported Effects:
Considerations for Glucagon Agonism
The glucagon component raises specific research questions:
Ongoing Monitoring
Phase 3 trials are examining:
Research Applications
Metabolic Studies
Retatrutide enables research into:
Comparative Research
Researchers can compare:
Combination Studies
Potential research combinations:
Future Directions
Regulatory Path
Research Questions
Ongoing studies aim to answer:
Getting Started with Retatrutide Research
Quality Considerations
When sourcing retatrutide for research:
Equipment Needed
Research Design
Consider:
Use our Peptide Planner to design your research protocol.
Retatrutide
5mg • 99%+ Purity
$99.99
In Stock
Frequently Asked Questions
What makes retatrutide different from semaglutide?
Retatrutide is a triple agonist (GLP-1, GIP, glucagon) while semaglutide only targets GLP-1. The addition of glucagon receptor agonism increases energy expenditure—the body burns more calories. Phase 2 trials showed ~24% weight loss with retatrutide vs ~15% with semaglutide. See our semaglutide comparison.
Is retatrutide FDA approved?
As of 2026, retatrutide is in phase 3 clinical trials and not yet FDA approved. It is available for research purposes only. Eli Lilly's TRIUMPH trial program is ongoing, with potential approval in 2026-2027.
How does the glucagon component affect blood sugar?
Despite glucagon's glucose-raising effects, the combined GLP-1 and GIP activity provides enough insulin-promoting effects to maintain glucose control. Clinical trials showed improved HbA1c alongside weight loss, indicating net glucose-lowering effects.
What is the dosing schedule for retatrutide?
Clinical trials used once-weekly subcutaneous injection with gradual titration over 20 weeks to reach 12mg. Starting doses were 0.5mg, escalating through 1mg, 2mg, 4mg, and 8mg before reaching maintenance dose. This slow titration minimizes GI side effects.
Can retatrutide be combined with other peptides?
Combination research is an active area of investigation. Any combination protocols should be carefully designed with appropriate controls and safety monitoring. The triple agonist nature of retatrutide may provide effects previously requiring multiple compounds.
What are the main side effects observed in trials?
Gastrointestinal effects (nausea, diarrhea, vomiting, constipation) were most common, similar to other GLP-1 agonists. These typically decreased with continued treatment and slower titration. Serious adverse events were uncommon in phase 2 trials.
Conclusion
Retatrutide represents a significant advancement in metabolic peptide research, combining three receptor mechanisms for potentially unprecedented effects on body weight and metabolism. The phase 2 trial results—with mean weight loss of 24.2%—suggest this triple agonist approach may redefine what's achievable in metabolic research.
For researchers, retatrutide offers a unique tool to study glucagon's role in energy expenditure alongside established incretin effects. As phase 3 data emerges, our understanding of optimal multi-receptor targeting will continue to evolve.
Use our dosing calculator for accurate research preparation.
Related Weight Loss Peptides
View All
This article is for informational purposes only. Retatrutide is an investigational compound sold for research purposes and is not approved for human use. All research should be conducted in accordance with applicable regulations.
